{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:06:33Z","timestamp":1778288793224,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40261-023-01249-8","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T12:03:28Z","timestamp":1680005008000},"page":"265-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sacubitril\/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System"],"prefix":"10.1007","volume":"43","author":[{"given":"Zhe","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yake","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2114-1059","authenticated-orcid":false,"given":"Yuehui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"1249_CR1","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1002\/ehf2.13124","volume":"7","author":"D Tomasoni","year":"2020","unstructured":"Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M. Heart failure in the last year: progress and perspective. ESC Heart Fail. 2020;7:3505\u201330. https:\/\/doi.org\/10.1002\/ehf2.13124.","journal-title":"ESC Heart Fail."},{"key":"1249_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","volume":"22","author":"A Groenewegen","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342\u201356.","journal-title":"Eur J Heart Fail"},{"key":"1249_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12872-019-1058-7","volume":"19","author":"PJ Kennel","year":"2019","unstructured":"Kennel PJ, Kneifati-Hayek J, Bryan J, Banerjee S, Sobol I, Lachs MS, et al. Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES). BMC Cardiovasc Disord. 2019;19:76. https:\/\/doi.org\/10.1186\/s12872-019-1058-7.","journal-title":"BMC Cardiovasc Disord"},{"key":"1249_CR4","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1056\/NEJMra021498","volume":"348","author":"M Jessup","year":"2003","unstructured":"Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007\u201318. https:\/\/doi.org\/10.1056\/NEJMra021498.","journal-title":"N Engl J Med"},{"key":"1249_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/CIRCHEARTFAILURE.121.008406","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Chai K, Du MH, Wang SF, Cai JP, Li YY, et al. Prevalence and incidence of heart failure among urban patients in China: a national population-based analysis. Circ Heart Fail. 2021;14:1127\u201335. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.008406.","journal-title":"Circ Heart Fail"},{"key":"1249_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/ejhf.1629","volume":"21","author":"G Hao","year":"2019","unstructured":"Hao G, Wang X, Chen Z, Zhang L, Zhang Y, Wei B, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012\u20132015. Eur J Heart Fail. 2019;21:1329\u201337. https:\/\/doi.org\/10.1002\/ejhf.1629.","journal-title":"Eur J Heart Fail"},{"key":"1249_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ejhf.1808","volume":"22","author":"M Metra","year":"2020","unstructured":"Metra M, Lucioli P. Corrigendum to \u201cPrevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012\u20132015\u201d [Eur J Heart Fail 2019;21:1329\u20131337]. Eur J Heart Fail. 2020;22:759. https:\/\/doi.org\/10.1002\/ejhf.1808.","journal-title":"Eur J Heart Fail"},{"key":"1249_CR8","first-page":"221","volume":"36","author":"CH Zou","year":"2021","unstructured":"Zou CH, Wang YH, Zhai M, Huang Y, Zhou Q, Zhuang XF, et al. 2020 clinical performance and quality measures for heart failure in China. Chin Circ J. 2021;36:221\u201338.","journal-title":"Chin Circ J."},{"key":"1249_CR9","first-page":"573","volume":"35","author":"L Ma","year":"2022","unstructured":"Ma L, Wang Z, Fan J, Hu S. Report on cardiovascular health and diseases in China 2021: an updated summary. Biomed Environ Sci. 2022;35:573\u2013603.","journal-title":"Biomed Environ Sci"},{"key":"1249_CR10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"key":"1249_CR11","unstructured":"Novartis Entresto\u00ae granted expanded indication in chronic heart failure by FDA. https:\/\/www.novartis.com\/news\/media-releases\/novartis-entresto-granted-expanded-indication-chronic-heart-failure-fda.. Accessed 8 Mar 2023."},{"key":"1249_CR12","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655.","journal-title":"N Engl J Med"},{"key":"1249_CR13","first-page":"612","volume":"29","author":"L Xinli","year":"2021","unstructured":"Xinli L. Chinese expert consensus on management of patients with heart failure and hypertension with preserved ejection fraction. Chin J Hypertens. 2021;29:612\u20137.","journal-title":"Chin J Hypertens."},{"key":"1249_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12933-021-01387-3","volume":"20","author":"CT Liao","year":"2021","unstructured":"Liao CT, Yang CT, Toh HS, Chang WT, Chang HY, Kuo FH, et al. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region. Cardiovasc Diabetol. 2021;20:204. https:\/\/doi.org\/10.1186\/s12933-021-01387-3.","journal-title":"Cardiovasc Diabetol"},{"key":"1249_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.750381","volume":"8","author":"CT Liao","year":"2021","unstructured":"Liao CT, Yang CT, Kuo FH, Lee MC, Chang WT, Tang HJ, et al. Cost-effectiveness evaluation of add-on empagliflozin in patients with heart failure and a reduced ejection fraction from the healthcare system\u2019s perspective in the Asia-Pacific region. Front Cardiovasc Med. 2021;8: 750381. https:\/\/doi.org\/10.3389\/fcvm.2021.750381.","journal-title":"Front Cardiovasc Med."},{"key":"1249_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.008638","volume":"15","author":"J Zhou","year":"2022","unstructured":"Zhou J, Liew D, Kaye DM, Zoungas S, Stub D. Cost-effectiveness of empagliflozin in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Qual Outcomes. 2022;15: e008638. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.121.008638.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1249_CR17","volume-title":"China health statistics yearbook 2021","author":"S Wu","year":"2021","unstructured":"Wu S, Yu S, Lei Z, Meng Q, Li T, Xu Z. China health statistics yearbook 2021. Beijing: Peking Union Medical College Press; 2021."},{"key":"1249_CR18","volume-title":"China guidelines for pharmacoeconomic evaluations: Chinese-English version","author":"SL Hu","year":"2020","unstructured":"Hu SL, Wu JH, Wu J, Dong CH, Li HC, Liu GE. China guidelines for pharmacoeconomic evaluations: Chinese-English version. 1st ed. Beijing: China Market Press; 2020.","edition":"1"},{"key":"1249_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-021-01112-8","volume":"40","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022;40:601\u20139. https:\/\/doi.org\/10.1007\/s40273-021-01112-8.","journal-title":"Pharmacoeconomics"},{"key":"1249_CR20","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40261-021-01079-6","volume":"41","author":"R Krittayaphong","year":"2021","unstructured":"Krittayaphong R, Permsuwan U. Cost-utility analysis of sacubitril-valsartan compared with enalapril treatment in patients with acute decompensated heart failure in Thailand. Clin Drug Investig. 2021;41:907\u201315. https:\/\/doi.org\/10.1007\/s40261-021-01079-6.","journal-title":"Clin Drug Investig"},{"key":"1249_CR21","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1002\/ehf2.12844","volume":"7","author":"YN Yao","year":"2020","unstructured":"Yao YN, Zhang RC, An T, Zhao XK, Zhang J. Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China. ESC Heart Fail. 2020;7:3582\u201392. https:\/\/doi.org\/10.1002\/ehf2.12844.","journal-title":"ESC Heart Fail."},{"key":"1249_CR22","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.21037\/jtd-22-463","volume":"14","author":"XH Lin","year":"2022","unstructured":"Lin XH, Lin MH, Liu MB, Huang WY, Nie XK, Chen ZC, et al. Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective. J Thorac Dis. 2022;14:1588\u201397. https:\/\/doi.org\/10.21037\/jtd-22-463.","journal-title":"J Thorac Dis"},{"key":"1249_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3389\/fphar.2020.01101","volume":"11","author":"Y Wu","year":"2020","unstructured":"Wu Y, Tian S, Rong PP, Zhang F, Chen Y, Guo XX, et al. Sacubitril-valsartan compared with enalapril for the treatment of heart failure: a decision-analytic Markov model simulation in China. Front Pharmacol. 2020;11:1101. https:\/\/doi.org\/10.3389\/fphar.2020.01101.","journal-title":"Front Pharmacol"},{"key":"1249_CR24","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/ejhf.2654","volume":"24","author":"AP Cai","year":"2022","unstructured":"Cai AP, Qiu WD, Zhou YL, Feng YQ, Chen JY, Xia S, et al. Clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association Database-Heart Failure Center Registry. Eur J Heart Fail. 2022;24:2048\u201362. https:\/\/doi.org\/10.1002\/ejhf.2654.","journal-title":"Eur J Heart Fail"},{"key":"1249_CR25","doi-asserted-by":"publisher","unstructured":"Xuan J, Tao L, Zhu S, Zhang M, Ni Q, Sun Q, et al. Real world survey of non-direct medical cost and quality of life for heart failure patients of China. China Health Insur. 2017:61\u20134.\u00a0https:\/\/doi.org\/10.19546\/j.issn.1674-3830.2017.3.013","DOI":"10.19546\/j.issn.1674-3830.2017.3.013"},{"key":"1249_CR26","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1007\/s11136-012-0342-0","volume":"22","author":"N Luo","year":"2013","unstructured":"Luo N, Li MH, Chevalier J, Lloyd A, Herdman M. A comparison of the scaling properties of the English, Spanish, French, and Chinese EQ-5D descriptive systems. Qual Life Res. 2013;22:2237\u201343. https:\/\/doi.org\/10.1007\/s11136-012-0342-0.","journal-title":"Qual Life Res"},{"key":"1249_CR27","unstructured":"National Healthcare Security Administration. Available at: http:\/\/www.nhsa.gov.cn\/. Accessed 20 Sep 2022."},{"key":"1249_CR28","unstructured":"Cost data. Available at: https:\/\/db.yaozh.com\/yaopinzhongbiao?comprehensivesearchcontent=sacubitril. Accessed 20 Sep 2022."},{"key":"1249_CR29","unstructured":"Cost data, accessed from the First Hospital of\u00a0Jilin University, Changchun, Jilin, Available at: https:\/\/www.jdyy.cn\/. Accessed 20 Sep 2022."},{"key":"1249_CR30","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40256-022-00542-9","volume":"22","author":"R Krittayaphong","year":"2022","unstructured":"Krittayaphong R, Permsuwan U. Cost-utility analysis of combination empagliflozin and standard treatment versus standard treatment alone in Thai heart failure patients with reduced or preserved ejection fraction. Am J Cardiovasc Drugs. 2022;22:577\u201390. https:\/\/doi.org\/10.1007\/s40256-022-00542-9.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1249_CR31","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jamacardio.2020.2822","volume":"5","author":"TA Gaziano","year":"2020","unstructured":"Gaziano TA, Fonarow GC, Velazquez EJ, Morrow DA, Braunwald E, Solomon SD. Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction. JAMA Cardiol. 2020;5:1236\u201344. https:\/\/doi.org\/10.1001\/jamacardio.2020.2822.","journal-title":"JAMA Cardiol."},{"key":"1249_CR32","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s40273-022-01182-2","volume":"40","author":"XY Dong","year":"2022","unstructured":"Dong XY, He XN, Wu J. Cost effectiveness of the first-in-class ARNI (sacubitril\/valsartan) for the treatment of essential hypertension in a Chinese setting. Pharmacoeconomics. 2022;40:1187\u2013205. https:\/\/doi.org\/10.1007\/s40273-022-01182-2.","journal-title":"Pharmacoeconomics"},{"key":"1249_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.959139","volume":"10","author":"YK Lou","year":"2022","unstructured":"Lou YK, Yu Y, Liu JX, Huang J. Sacubitril-valsartan for the treatment of hypertension in China: a cost-utility analysis based on meta-analysis of randomized controlled trials. Front Public Health. 2022;10: 959139. https:\/\/doi.org\/10.3389\/fpubh.2022.959139.","journal-title":"Front Public Health"},{"key":"1249_CR34","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"1249_CR35","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"key":"1249_CR36","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong JJ, Lefkowitz MP, Rizkala AR, et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"key":"1249_CR37","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"key":"1249_CR38","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"key":"1249_CR39","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1002\/ehf2.13921","volume":"9","author":"SQ Chen","year":"2022","unstructured":"Chen SQ, Huang ZD, Liang Y, Zhao XL, Aobuliksimu X, Wang B, et al. Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort. ESC Heart Fail. 2022;9:2336\u201347. https:\/\/doi.org\/10.1002\/ehf2.13921.","journal-title":"ESC Heart Fail."},{"key":"1249_CR40","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.cardfail.2017.09.014","volume":"23","author":"YH Zhang","year":"2017","unstructured":"Zhang YH, Zhang J, Butler J, Yang XM, Xie PY, Guo DS, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China Heart Failure (China-HF) Registry. J Card Fail. 2017;23:868\u201375. https:\/\/doi.org\/10.1016\/j.cardfail.2017.09.014.","journal-title":"J Card Fail"},{"key":"1249_CR41","first-page":"108","volume":"29","author":"PL Bu","year":"2021","unstructured":"Bu PL, Lu XZ, Shi LW, Feng YQ, Liu LS, Liu M, et al. Clinical application of sacubitril valsartan in patients with hypertension recommended by Chinese experts. Chin J Hypertens. 2021;29:108\u201314.","journal-title":"Chin J Hypertens."},{"key":"1249_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.946399","volume":"9","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Xie J. Cost-effectiveness of adding empagliflozin to the standard therapy for heart failure with preserved ejection fraction from the perspective of healthcare systems in China. Front Cardiovasc Med. 2022;9: 946399. https:\/\/doi.org\/10.3389\/fcvm.2022.946399.","journal-title":"Front Cardiovasc Med."},{"key":"1249_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40256-022-00550-9","volume":"23","author":"Y Lou","year":"2023","unstructured":"Lou Y, Hu T, Huang J. Cost-effectiveness of adding empagliflozin to standard treatment for heart failure with preserved ejection fraction patients in China. Am J Cardiovasc Drugs. 2023;23:47\u201357. https:\/\/doi.org\/10.1007\/s40256-022-00550-9.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1249_CR44","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet. 2020;396:819\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(20)31824-9.","journal-title":"Lancet"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01249-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01249-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01249-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:27:13Z","timestamp":1681313233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01249-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1249"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01249-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"9 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Zhe Wang, Yake Lou, Qi Wang, Min Sun, Xiaonan Li, Yinghui Wang, and Yuehui Wang declare they have no conflicts of interest in relation to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study does not contain any studies with human participants or animals, performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"YW conceptualized the idea and designed the protocol. ZW and YL drafted the manuscript. ZW, QW, MS, XL, and YW participated in the data collection. YL developed the model.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}